If you spend any time around healthcare investing or strategy, the name Candesic tends to come up sooner or later. It is not a household brand in the way that the giant strategy firms are, and that is rather the point. Candesic has built its reputation by going deep instead of going wide, planting itself firmly in healthcare and the sectors that orbit it, and becoming the kind of advisor that investors call when the stakes are high and the subject matter is genuinely complicated. In a world full of generalist consultants who can talk a good game about almost anything, Candesic has taken the opposite bet: know one thing extraordinarily well and let that expertise do the talking. This article digs into who they are, how they got here, and why a relatively small London firm has managed to punch so far above its weight.
What Candesic Actually Is
At its core, Candesic is a specialist management consulting firm with a heavy focus on healthcare, pharmaceuticals, life sciences, and medtech. That is a deliberately narrow lane, and it shows up in everything they do. Rather than trying to advise clients on retail one week and energy the next, the firm concentrates almost entirely on the business of keeping people healthy and the companies, investors, and public bodies wrapped around that mission. Their work spans strategy, commercial and vendor due diligence, digital transformation, and mergers and acquisitions or growth support. The tagline they have leaned on for years, “CEO level clarity with R&D level insight,” captures the dual personality they are going for: boardroom-ready advice that is grounded in genuine scientific and clinical understanding rather than slide-deck buzzwords. It is a positioning that only really works if you actually have the depth to back it up, which is where their hiring philosophy comes in.
The Origin Story
Candesic was founded back in 2002 by Dr Leonid Shapiro and Marc Kitten, and that founding date matters more than it might first appear. Launching a healthcare-focused boutique consultancy in the early 2000s meant betting that healthcare would become an increasingly investable, increasingly sophisticated sector — a bet that has aged remarkably well. Over the two decades since, private equity has flooded into healthcare, regulatory complexity has multiplied, and the demand for advisors who can speak both clinical and financial fluently has only grown. The founders, one bringing a doctorate and the other a strategic and commercial sensibility, essentially built the firm around the idea that the best healthcare advice sits at the intersection of medicine and money. Starting lean and specialist, rather than chasing scale across every industry, gave them the freedom to build a distinct identity that has carried them through more than twenty years and several economic cycles.
Why the Healthcare Specialism Works
There is a real strategic logic behind staying so tightly focused, and it is worth pausing on. Healthcare is one of those sectors where surface-level analysis can be actively dangerous. A consultant who does not understand reimbursement structures, clinical pathways, regulatory regimes, or the day-to-day realities of how care is actually delivered can produce a beautiful financial model that falls apart the moment it meets reality. Candesic’s whole proposition is that they will not make those rookie mistakes, because the people doing the work include medical doctors and scientists alongside the strategists. When an investor is weighing up a multi-million-pound acquisition of a care home group, a diagnostics business, or a pharma services company, that depth becomes the difference between a confident decision and an expensive guess. Specialisation, in this context, is not a limitation. It is the entire value proposition, and it is what lets a smaller firm compete credibly against far larger rivals.
The Service Lines, Unpacked
Candesic groups its work into a handful of core offerings, and each one tells you something about who their clients are. Strategy work covers the big questions — where to play, how to grow, how to position a business for the next phase of its life. Commercial and vendor due diligence is arguably their bread and butter, the kind of intense, deadline-driven analysis that supports a transaction by pressure-testing whether a target business is really worth what someone is about to pay for it. Their digital practice reflects how much technology now reshapes care delivery, from telehealth to data analytics to automation. And their M&A and growth support helps businesses and their backers navigate deals and scale-up journeys. What ties these together is that they are all transaction-adjacent or transformation-adjacent; this is a firm built to be useful at the moments when serious money and serious change are on the table, not just for producing reports that gather dust.
The Due Diligence Engine
It is worth giving commercial due diligence its own spotlight, because this is where a lot of Candesic’s reputation is forged. Due diligence in private equity is a brutal, high-pressure discipline. You are handed a business, given a tight window, and asked to figure out whether the market is real, whether the growth story holds up, whether the competition will eat the company alive, and whether the numbers in the management presentation survive contact with reality. Getting this wrong can torpedo a fund’s returns, so investors do not hand the work to just anyone. Candesic has built a track record across a large volume of buy-side engagements, advising private equity funds and other investors as they weigh up healthcare and adjacent targets. The combination of speed, rigour, and genuine sector knowledge is exactly what makes a diligence provider trusted, and it explains why the firm keeps getting called back for repeat work.
Deep Ties to Private Equity
A huge slice of Candesic’s client base sits in the world of private equity and private investment, and understanding that relationship explains a lot about how the firm operates. They work with global PE funds, other private investors, and crucially the portfolio companies those investors own. That last point matters because the relationship does not end when a deal closes. An investor who has just bought a healthcare business often wants ongoing strategic support to actually deliver the growth they paid for, and Candesic is positioned to help across that full lifecycle — from the diligence that informs the purchase, through to the value-creation work afterwards. This kind of embedded, long-term relationship with the investment community is gold dust for a consultancy, because it generates repeat business and deep institutional knowledge of how investors think, what keeps them up at night, and what they actually need from an advisor.
Serving the Public Sector and the NHS
It would be easy to assume a firm so plugged into private equity would have little time for the public sector, but Candesic has made a point of working with public bodies too, including the NHS. This is a meaningful part of their identity rather than an afterthought. The logic is consistent with their broader mission of improving care outcomes: if you genuinely care about how healthcare is delivered, you cannot ignore the public institutions that deliver the overwhelming majority of care in markets like the UK. Their team includes medical doctors with first-hand experience of the realities and challenges public health systems face, which lends real credibility when advising governments and public organisations. Advising the public sector requires a different sensibility from advising a profit-driven investor — the constraints, the politics, and the definitions of success all differ — and being able to operate credibly on both sides of that line is a genuine strength.
A Global Footprint From a London Base
Candesic is headquartered in London, but it is far from a purely British operation. The firm has built out additional offices across France, Spain, Italy, and India, giving it a European spine plus a foothold in one of the world’s most important talent and growth markets. Their engagements have reached well beyond Europe too, touching the Middle East, the Americas, and Australia over the years. This geographic spread matters for a couple of reasons. First, healthcare investing is increasingly cross-border, and clients want advisors who can understand markets in multiple countries rather than being boxed into one. Second, the international presence lets the firm tap into different talent pools and bring varied perspectives to its work. For a firm of its size, maintaining offices across several countries is a real statement of ambition, signalling that it intends to be a serious player on a continental and even global stage, not just a London boutique.
The People Behind the Work
Any consultancy is ultimately only as good as its people, and Candesic leans hard into this. The firm runs with a relatively compact team of around forty professionals, which is tiny compared with the armies fielded by the major strategy houses. But that smallness is intentional and it reinforces the specialist model. What is distinctive about the team is its blend of disciplines: medical doctors, scientists, business strategists, and technology specialists working side by side. That mix is unusual in consulting, where the default hire is often a generalist analyst with a strong CV but no deep domain expertise. By bringing genuine clinical and scientific knowledge in-house, Candesic can interrogate a healthcare business in ways a generalist simply cannot. The firm also clearly cares about attracting strong talent, promoting its careers opportunities actively and presenting itself as a place where ambitious people can do interesting, high-impact work in a focused field.
Thought Leadership and the Content Push
In recent years Candesic has invested noticeably in thought leadership, and this is a smart move for a specialist firm trying to stay top of mind. They produce written commentary on healthcare markets — covering everything from ophthalmology to private dentistry to the regulatory scrutiny that lands on healthcare subsectors — and they have built out a podcast and video presence under the banner “Candesic In Conversation.” The podcast features interviews with leaders, innovators, and decision-makers across healthcare, social care, medtech, and pharma, with senior figures from the firm exploring topics like teleradiology, the impact of artificial intelligence on diagnostics, and the investment case for social care technology. This content strategy does double duty. It positions the firm as a genuine authority that has informed views worth listening to, and it quietly demonstrates the depth of expertise that makes their consulting work credible. For a boutique competing against bigger names, being seen as a source of insight is a powerful way to build trust before a client even picks up the phone.
Beyond Healthcare: The Other Practices
While healthcare and social care are unmistakably the heart of the business, Candesic’s reach extends into a few adjacent areas that are easy to overlook. The firm has practices touching aerospace, defence and security, alongside technology and telecoms work. At first glance these might seem like odd bedfellows for a healthcare-focused shop, but there is a thread connecting them: they are all complex, technically demanding, often regulated sectors where the same skills — rigorous analysis, deep technical understanding, and the ability to advise investors and operators on big decisions — transfer well. It is also a sensible way to diversify without abandoning the specialist DNA. By extending into sectors that reward the same analytical muscles, the firm hedges against being overly dependent on a single market while still avoiding the trap of becoming a do-everything generalist. That said, nobody should mistake the firm’s identity; healthcare remains the centre of gravity around which everything else orbits.
What It’s Like Inside the Firm
Reviews from people who have worked at Candesic paint a generally positive picture, with the firm landing a respectable rating on employee review platforms based on dozens of reviews. The recurring themes from current and former staff tend to be that the work is demanding but rewarding, that the partners are seen as supportive and approachable, and that the firm attracts high-quality assignments that make it a strong environment for learning and advancement. Consultancy is hard work anywhere, and Candesic is no exception, but the trade-off seems to be genuine exposure to interesting problems and a culture that several reviewers describe as values-driven, with a sincere focus on improving patient outcomes rather than just chasing fees. Like any firm there are critiques too — comments about communication and training have surfaced — but the overall sense is of a place run by people who care about doing good work in a field they take seriously.
Why Candesic Punches Above Its Weight
Put all of this together and you start to understand how a forty-person firm has stayed relevant and respected for more than two decades in a field crowded with much larger competitors. Candesic has found a defensible niche and defended it well. By refusing to dilute its focus, it has built a depth of expertise that is hard for generalists to match and expensive for newcomers to replicate. By embedding itself with the private equity community while also serving the public sector, it has diversified its client base without losing coherence. And by investing in talent and thought leadership, it has built a brand that carries weight far beyond what its headcount might suggest. In an industry where bigger is often assumed to be better, Candesic is a useful reminder that focus, credibility, and genuine domain knowledge can be just as powerful as scale.
FAQs
What does Candesic do?
Candesic is a specialist management consultancy focused on healthcare, pharma, life sciences, and medtech. It advises investors, corporates, and public bodies on strategy, commercial due diligence, digital transformation, and M&A or growth, with a particular strength in supporting private equity deals.
Who founded Candesic and when?
Candesic was founded in 2002 by Dr Leonid Shapiro and Marc Kitten. The pair built the firm around the idea that the best healthcare advice combines genuine clinical and scientific depth with sharp commercial strategy, a philosophy that still defines it today.
Where is Candesic based?
Candesic is headquartered in London, with additional offices in France, Spain, Italy, and India. Its engagements have reached across Europe, the Middle East, the Americas, and Australia, giving the boutique a surprisingly international footprint.
Does Candesic only work in healthcare?
Healthcare and social care are the firm’s core, but not its entire story. Candesic also runs practices touching aerospace, defence and security, plus technology and telecoms, applying the same analytical rigour to other complex, regulated sectors.
Is Candesic a good place to work?
Reviews are broadly positive, with the firm earning a solid employee rating across dozens of reviews. Staff tend to describe demanding but rewarding work, supportive partners, and high-quality assignments that make it a strong environment for learning and career growth.
Read also: Toulouse Holliday
Conclusion
Candesic is, in many ways, a textbook example of how a specialist consultancy can carve out a durable place in a competitive market. Founded in 2002 by Dr Leonid Shapiro and Marc Kitten, it has spent more than twenty years becoming one of the go-to advisors for healthcare strategy and due diligence, trusted by private equity investors, healthcare corporates, and public bodies alike. Its formula is not complicated to describe but is hard to copy: stay focused on healthcare and its adjacent sectors, hire people with real clinical and scientific depth, deliver rigorous work under pressure, and back it all with genuine thought leadership. Whether you are an investor sizing up a healthcare deal, an operator plotting your next phase of growth, or simply someone curious about the firms shaping the business of care, Candesic is a name worth knowing. It may not shout the loudest, but in its chosen field it has earned a reputation that speaks for itself.